(BBIO) BridgeBio Pharma - Ratings and Ratios
ATTR-CM, Achondroplasia, Hypochondroplasia, ADH1, LGMD2I
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 54.6% |
| Value at Risk 5%th | 80.0% |
| Relative Tail Risk | -11.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.04 |
| Alpha | 143.92 |
| CAGR/Max DD | 2.14 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.372 |
| Beta | 1.009 |
| Beta Downside | 0.804 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.08% |
| Mean DD | 20.41% |
| Median DD | 19.76% |
Description: BBIO BridgeBio Pharma January 07, 2026
BridgeBio Pharma (NASDAQ: BBIO) is a commercial-stage biopharma founded in 2015 and based in Palo Alto, California. It focuses on developing small-molecule and gene-therapy treatments for rare genetic disorders and oncology, leveraging a platform that pairs disease-genetics insight with in-house drug discovery.
The current pipeline includes: (1) Attruby, a next-generation oral TTR stabilizer in late-stage development for transthyretin-mediated cardiomyopathy (ATTR-CM); (2) low-dose infigratinib, an FGFR1-3 selective inhibitor advancing in a Phase 3 double-blind trial for achondroplasia and in a Phase 2/3 study for hypochondroplasia; (3) Encaleret, a CaSR antagonist in Phase 3 for autosomal dominant hypocalcemia type 1; and (4) BBP-418, a glycosylation-substrate pro-drug in Phase 3 for limb-girdle muscular dystrophy type 2I/R9. The company also maintains collaborations with Alexion, Stanford, Leidos, and Novartis to broaden its Mendelian and oncology portfolio.
As of the latest 10-Q (Q2 2024), BridgeBio reported a market capitalization of roughly $2.4 billion, cash and equivalents of $450 million, and a cash burn rate of about $120 million per quarter, giving it just over a year of runway without additional financing. The biotech sector is benefiting from a 10-12 % CAGR in rare-disease drug approvals and increasing payer willingness to reimburse high-value therapies, which supports higher valuation multiples for companies with late-stage assets.
For a deeper, data-driven look at BBIO’s valuation and risk profile, you might explore the analyst tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-797.1m TTM) > 0 and > 6% of Revenue (6% = 21.2m TTM) |
| FCFTA -0.60 (>2.0%) and ΔFCFTA 9.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 176.0% (prev 140.2%; Δ 35.81pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.59 (>3.0%) and CFO -584.8m > Net Income -797.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (190.5m) change vs 12m ago 1.06% (target <= -2.0% for YES) |
| Gross Margin 95.78% (prev 98.90%; Δ -3.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.54% (prev 32.75%; Δ 9.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.63 (EBITDA TTM -677.3m / Interest Expense TTM 121.3m) >= 6 (WARN >= 3) |
Altman Z'' -14.58
| (A) 0.62 = (Total Current Assets 839.4m - Total Current Liabilities 216.6m) / Total Assets 998.2m |
| (B) -3.63 = Retained Earnings (Balance) -3.63b / Total Assets 998.2m |
| warn (B) unusual magnitude: -3.63 — check mapping/units |
| (C) -0.82 = EBIT TTM -682.6m / Avg Total Assets 831.6m |
| (D) -1.24 = Book Value of Equity -3.63b / Total Liabilities 2.92b |
| Total Rating: -14.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 44.97
| 1. Piotroski 1.0pt |
| 2. FCF Yield -3.73% |
| 3. FCF Margin data missing |
| 4. Debt/Equity -0.96 |
| 5. Debt/Ebitda -1.80 |
| 7. RoE 46.63% |
| 8. Rev. Trend 46.69% |
| 9. EPS Trend -3.37% |
What is the price of BBIO shares?
Over the past week, the price has changed by -5.64%, over one month by -0.57%, over three months by +33.49% and over the past year by +150.66%.
Is BBIO a buy, sell or hold?
- Strong Buy: 10
- Buy: 6
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 86.6 | 17.3% |
| Analysts Target Price | 86.6 | 17.3% |
| ValueRay Target Price | 83.8 | 13.6% |
BBIO Fundamental Data Overview January 03, 2026
P/B = 123.6828
Beta = 1.257
Revenue TTM = 353.8m USD
EBIT TTM = -682.6m USD
EBITDA TTM = -677.3m USD
Long Term Debt = 1.85b USD (from longTermDebt, last quarter)
Short Term Debt = 5.29m USD (from shortTermDebt, last quarter)
Debt = 1.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.22b USD (from netDebt column, last quarter)
Enterprise Value = 15.95b USD (14.74b + Debt 1.86b - CCE 645.9m)
Interest Coverage Ratio = -5.63 (Ebit TTM -682.6m / Interest Expense TTM 121.3m)
FCF Yield = -3.73% (FCF TTM -595.2m / Enterprise Value 15.95b)
FCF Margin = -168.2% (FCF TTM -595.2m / Revenue TTM 353.8m)
Net Margin = -225.3% (Net Income TTM -797.1m / Revenue TTM 353.8m)
Gross Margin = 95.78% ((Revenue TTM 353.8m - Cost of Revenue TTM 14.9m) / Revenue TTM)
Gross Margin QoQ = 94.56% (prev 96.70%)
Tobins Q-Ratio = 15.98 (Enterprise Value 15.95b / Total Assets 998.2m)
Interest Expense / Debt = 0.63% (Interest Expense 11.7m / Debt 1.86b)
Taxrate = 0.83% (-1.54m / -186.5m)
NOPAT = -677.0m (EBIT -682.6m * (1 - 0.83%)) [loss with tax shield]
Current Ratio = 3.88 (Total Current Assets 839.4m / Total Current Liabilities 216.6m)
Debt / Equity = -0.96 (negative equity) (Debt 1.86b / totalStockholderEquity, last quarter -1.93b)
Debt / EBITDA = -1.80 (negative EBITDA) (Net Debt 1.22b / EBITDA -677.3m)
Debt / FCF = -2.04 (negative FCF - burning cash) (Net Debt 1.22b / FCF TTM -595.2m)
Total Stockholder Equity = -1.71b (last 4 quarters mean from totalStockholderEquity)
RoA = -95.85% (Net Income -797.1m / Total Assets 998.2m)
RoE = 46.63% (negative equity) (Net Income TTM -797.1m / Total Stockholder Equity -1.71b)
RoCE = -481.7% (out of range, set to none) (EBIT -682.6m / Capital Employed (Equity -1.71b + L.T.Debt 1.85b))
RoIC = -625.6% (out of range, set to none) (NOPAT -677.0m / Invested Capital 108.2m)
WACC = 8.71% (E(14.74b)/V(16.60b) * Re(9.73%) + D(1.86b)/V(16.60b) * Rd(0.63%) * (1-Tc(0.01)))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.50%
Fair Price DCF = unknown (Cash Flow -595.2m)
EPS Correlation: -3.37 | EPS CAGR: 14.10% | SUE: 0.39 | # QB: 0
Revenue Correlation: 46.69 | Revenue CAGR: 81.59% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.60 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.77 | Chg30d=-0.047 | Revisions Net=+1 | Growth EPS=+44.4% | Growth Revenue=+79.1%
Additional Sources for BBIO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle